nvls_Current folio

0001558370-16-009534.txt : 20161107 0001558370-16-009534.hdr.sgml : 20161107 20161107164607 ACCESSION NUMBER: 0001558370-16-009534 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161107 DATE AS OF CHANGE: 20161107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nivalis Therapeutics, Inc. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 161978701 BUSINESS ADDRESS: STREET 1: 3122 STERLING CIRCLE, SUITE 200 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-945-7700 MAIL ADDRESS: STREET 1: 3122 STERLING CIRCLE, SUITE 200 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 10-Q 1 nvls-20160930x10q.htm 10-Q nvls_Current folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016



◻

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-37449

Nivalis Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)


Delaware		20-8969493
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3122 Sterling Circle, Suite 200 Boulder, Colorado		80301
(Address of principal executive offices)		(Zip Code)

(720) 945-7700

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ◻

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	◻		Accelerated filer	☒
Non-accelerated filer	◻	(Do not check if a smaller reporting company)	Smaller reporting company	◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ◻ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 31, 2016 was 15,543,469.

Table of Contents

NIVALIS THERAPEUTICS, INC.

FORM 10-Q

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS	3

	Balance Sheets	3

	Statements of Operations and Comprehensive Loss	4

	Statement of Stockholders’ Equity	5

	Statements of Cash Flows	6

	NOTES TO UNAUDITED FINANCIAL STATEMENTS	7

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	12

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	20

ITEM 4.	CONTROLS AND PROCEDURES	20

PART II. OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	21

ITEM 1A.	RISK FACTORS	21

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	21

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	21

ITEM 4.	MINE SAFETY DISCLOSURES	21

ITEM 5.	OTHER INFORMATION	21

ITEM 6.	EXHIBITS	21

	SIGNATURES	23

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

Nivalis Therapeutics, Inc.

Balance Sheets

(In thousands, except for share amounts)


	September 30,		December 31,
	2016		2015
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	16,168	$	24,991
Marketable securities		50,019		62,263
Prepaid expenses and other current assets		843		432
Total current assets		67,030		87,686

Property and equipment and other assets, net		312		223
Total assets	$	67,342	$	87,909

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,012	$	994
Accrued direct program expenses		2,837		1,555
Accrued employee benefits		1,345		1,675
Accrued other liabilities		44		195
Total current liabilities		5,238		4,419

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding for both periods presented		—		—
Common stock, $0.001 par value; 200,000,000 shares authorized for both periods presented; 15,505,334 and 15,462,030 shares issued and outstanding, respectively		16		15
Additional paid-in capital		234,670		232,309
Accumulated other comprehensive income		5		3
Accumulated deficit		(172,587)		(148,837)
Total stockholders’ equity		62,104		83,490
Total liabilities and stockholders’ equity	$	67,342	$	87,909

The accompanying notes are an integral part of these financial statements.

Table of Contents

Nivalis Therapeutics, Inc.

Statements of Operations and Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
Revenue	$	—		—	$	—	$	—

Operating expenses:
Research and development		5,669		4,279		17,660		11,761
General and administrative		1,879		1,822		6,418		4,507
Loss from operations		(7,548)		(6,101)		(24,078)		(16,268)

Interest income		115		12		328		13
Net loss attributable to common stockholders	$	(7,433)	$	(6,089)	$	(23,750)	$	(16,255)

Unrealized gains (losses) on marketable securities		(18)		15		2		15
Comprehensive loss	$	(7,451)	$	(6,074)	$	(23,748)	$	(16,240)

Weighted average shares outstanding - basic and diluted		15,504		15,451		15,476		7,322
Net loss per share - basic and diluted	$	(0.48)	$	(0.39)	$	(1.53)	$	(2.22)

The accompanying notes are an integral part of these financial statements.

Table of Contents

Nivalis Therapeutics, Inc.

Statement of Stockholders’ Equity

(In thousands)

(Unaudited)



				Additional		Accumulated Other				Total
	Common Stock			Paid‑in		Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Capital		Income		Deficit		Equity
Balance as of December 31, 2015	15,462	$	15	$	232,309	$	3	$	(148,837)	$	83,490
Employee stock-based compensation expense	—		—		2,259		—		—		2,259
Issuance of common stock under employee share plans and awards	43		1		102		—		—		103
Unrealized gains on marketable securities	—		—		—		2		—		2
Net loss	—		—		—		—		(23,750)		(23,750)
Balance as of September 30, 2016	15,505	$	16	$	234,670	$	5	$	(172,587)	$	62,104

The accompanying notes are an integral part of these financial statements.

Table of Contents

Nivalis Therapeutics, Inc.

Statements of Cash Flows

(In thousands)

(Unaudited)


	Nine Months Ended
	September 30,
	2016		2015
Operating activities
Net loss	$	(23,750)	$	(16,255)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		104		47
Stock-based compensation expense		2,259		718
Changes in operating assets and liabilities:
Prepaid expenses and other		(514)		(366)
Accounts payable		18		623
Accrued direct program expenses		1,282		213
Accrued employee benefits		(330)		1,126
Accrued other liabilities		(151)		88
Net cash used in operating activities		(21,082)		(13,806)

Investing activities
Purchases of property and equipment		(90)		(142)
Purchases of marketable securities		(66,154)		(35,081)
Proceeds from sales and maturities of marketable securities		78,400		—
Net cash provided by (used in) investing activities		12,156		(35,223)

Financing activities
Proceeds from issuance of common stock, net of offering costs		—		78,772
Proceeds from employee stock purchases and stock options exercised		103
Net cash provided by financing activities		103		78,772

Net increase (decrease) in cash and cash equivalents		(8,823)		29,743
Cash and cash equivalents, beginning of period		24,991		27,812
Cash and cash equivalents, end of period	$	16,168	$	57,555

Supplemental disclosures of cash flow information
Conversion of convertible preferred stock to common stock	$	—	$	41,880

The accompanying notes are an integral part of these financial statements.

Table of Contents

NIVALIS THERAPEUTICS, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

1. Organization and Description of Business

Nivalis Therapeutics, Inc. (the “Company” or “Nivalis”), incorporated in Delaware on August 1, 2012, is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with cystic fibrosis. In addition to developing innovative solutions intended to extend and improve the lives of people with cystic fibrosis, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

2. Liquidity Risks

The Company has incurred operating losses and has an accumulated deficit as a result of ongoing research and development spending. As of September 30, 2016, the Company had an accumulated deficit of $172.6 million. For the nine months ended September 30, 2016, net loss was $23.8 million and net cash used in operating activities was $21.1 million. The Company anticipates that operating losses and net cash used in operating activities will continue and substantially increase over the next several years as it expands development activities for its current product candidate cavosonstat (N91115).

The Company has historically financed its operations primarily through the sale of its equity and debt securities. The Company will continue to be dependent upon such sources of funds until it is able to generate positive cash flows from its operations. Management has determined that the Company’s existing cash, cash equivalents and marketable securities as of September 30, 2016 will be sufficient to fund operations at least through the next twelve months.

The Company expects to fund future operations through the sale of its equity securities, incurring debt, entering into partnerships, obtaining grants, or seeking other nondilutive sources of financing. There can be no assurance that sufficient funds from these sources will be available to the Company when needed or at all or on terms that are favorable to the Company. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it would have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. It could force the Company to delay, limit, reduce or terminate research and development programs and commercialization efforts or cause the Company to cease operations in full.

3. Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include all adjustments necessary for the presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements and accompanying notes, including accrued liabilities and the fair value-based measurement of equity instruments. Actual results could differ materially from those estimates. The Company evaluates its estimates and assumptions as facts and circumstances dictate.

Unaudited Interim Financial Data

The balance sheet at December 31, 2015 was derived from the Company’s audited financial statements, but does not include all the disclosures required by GAAP. These financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2015. The accompanying interim financial statements as of September 30, 2016 and for the three and nine months ended September 30, 2016 and 2015, are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements, pursuant to the rules and regulations of the SEC for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary to fairly state the Company’s financial position as of September 30, 2016 and the results of operations and cash flows for the three and

Table of Contents

nine months ended September 30, 2016 and 2015. The results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any future interim period.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing and demand money market accounts.

Marketable Securities

The Company has designated marketable securities as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are classified as available-for-sale are carried at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company’s then current intent and ability to sell the security if it is required to do so. The cost of securities sold is based on the specific identification method. All marketable securities are subject to a periodic impairment review. The Company will recognize an impairment charge when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.

Accrued Direct Program Expenses

Substantial portions of the Company’s preclinical studies and clinical trials, including the manufacture and packaging of drug supplies are performed by third-party laboratories, contract manufacturing organizations, medical centers, contract research organizations and other service providers (collectively vendors). These vendors generally bill monthly or quarterly for services performed or upon achieving certain milestones. For preclinical studies and product development and manufacturing, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon patient enrollment and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported by these vendors using software tracking systems, or through clinical site visits and vendor correspondence. Company estimates depend on the timeliness and accuracy of the data provided by these vendors regarding the status of each program and total program spending. The Company periodically evaluates these estimates to determine if adjustments are necessary or appropriate based on information received.

Comprehensive Loss

Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on the Company’s investments in available-for-sale marketable securities. The Company presents comprehensive loss and its components in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2016.

Net Loss per Share

The Company reports net loss per share in accordance with the standard codification of ASC “Earnings per Share” (“ASC 260”). Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could be exercised or converted into common shares, and is computed by dividing net loss by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share excludes the impact of options to purchase common stock, restricted stock units and warrants to purchase common stock, as the effect would be anti-dilutive. During a loss period, the assumed exercise of in-the-money stock options and other potentially diluted instruments has an anti-dilutive effect and therefore, these instruments are excluded from the computation of dilutive earnings per share.

Table of Contents

Recent Accounting Pronouncements

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, as well as classification within the statement of cash flows. The guidance will be effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently evaluating the impact of the new pronouncement on its financial statements.

For additional discussion of recent accounting pronouncements please refer to Note 3, “Summary of Significant Accounting Policies – Recent Accounting Pronouncements”, in the Company’s previously filed Annual Report on Form 10-K for the year ended December 31, 2015. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2016 that had a material effect on its financial statements.

Fair Value of Financial Instruments

The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts payable, accrued direct program expenses, and accrued employee benefits, and other financial instruments included within current assets or current liabilities.

Fair Value Measurements

In general, asset and liability fair values are determined using the following categories:

Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities.

Level 2 – inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.

Level 3 – inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own estimates about the assumptions that a market participant would use in pricing as asset.

The Company’s financial instruments, including money market investments, reverse repurchase agreements, corporate debt securities, U.S. Treasury securities and obligations of U.S. government agencies, are measured at fair value on a recurring basis. There were no transfers between levels for the nine months ended September 30, 2016.

Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of September 30, 2016 and December 31, 2015 (in thousands):


			Quoted prices		Quoted prices				Quoted prices		Quoted prices
			in active		for similar assets				in active		for similar assets
			markets for		observable in the				markets for		observable in the
	September 30,		identical assets		marketplace		December 31,		identical assets		marketplace
Description	2016		(Level 1)		(Level 2)		2015		(Level 1)		(Level 2)
Assets measured at fair value:
Money market investments	$	8,465	$	8,465	$	—	$	12,131	$	12,131	$	—
U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements		55,018		—		55,018		73,261		—		73,261

Table of Contents

4. Cash, Cash Equivalents and Marketable Securities

The following is a summary of cash, cash equivalents and marketable securities as of September 30, 2016 and December 31, 2015 (in thousands):


			Gross unrealized		Gross unrealized		Fair market
	Amortized Cost		gains		losses		value
September 30, 2016
Cash	$	2,704	$	-	$	-	$	2,704
Money market funds		8,465		-		-		8,465
Reverse repurchase agreement		5,000		-		-		5,000
U.S Treasury securities and obligations of U.S. government agencies		23,144		14		-		23,158
Corporate debt securities		26,869		3		(12)		26,860
Total for September 30, 2016	$	66,182	$	17	$	(12)	$	66,187

December 31, 2015
Cash	$	1,862	$	–	$	–	$	1,862
Money market funds		12,131		–		–		12,131
Reverse repurchase agreements		6,000		–		–		6,000
U.S Treasury securities and obligations of U.S. government agencies		28,982		4		(7)		28,979
Corporate debt securities		38,276		22		(16)		38,282
Total for December 31, 2015	$	87,251	$	26	$	(23)	$	87,254

5. Stockholders’ Equity

Concurrent with the Company’s initial public offering completed in June 2015 (the “IPO”), the Company increased its authorized number of shares of common stock to 200,000,000 shares, eliminated its authorized shares of convertible preferred stock and authorized 10,000,000 shares of preferred stock for future issuance.

Common Stock

On June 22, 2015, the Company completed its IPO of 6,325,000 shares of its common stock, including 875,000 shares from the exercise of the underwriters’ over-allotment option. The Company received proceeds of $78.8 million from its IPO, net of $9.8 million in expenses and underwriters’ discounts and commissions relating to the issuance and distribution of the securities.

On April 18, 2016, in connection with the appointment of the Company’s new Chief Medical Officer, the Company approved a grant of stock options to purchase 108,333 shares of the Company’s common stock (the “Options”) and 216,667 restricted stock units (“RSUs”). The Options and RSUs were issued pursuant to a separate Notice of Inducement Stock Option Grant and Inducement Stock Option Agreement and Notice of Restricted Stock Unit Inducement Grant and Inducement Restricted Stock Unit Agreement and are considered inducement grants made in accordance with NASDAQ Listing Rule 5635(c)(4).

On July 5, 2016, the Company filed a registration statement on Form S-3 that was declared effective on July 14, 2016 registering (i) the offering, issuance and sale of up to $125,000,000 in the aggregate of an indeterminate number of shares of common stock and preferred stock, an indeterminate principal amount of debt securities and an indeterminate number of warrants and (ii) the resale of up to 3,732,412 shares of common stock by selling stockholders pursuant to a base prospectus that forms a part of the registration statement. The registration statement also registers the offering, issuance and sale of the Company’s common stock having up to a maximum aggregate offering price of $20,000,000 that may be issued and sold in an at-the-market offering under a sales agreement the Company entered into with Cowen and Company, LLC on July 5, 2016 pursuant to a sales agreement prospectus that forms a part of the registration statement. The $20,000,000 of common stock that may be sold under the sales agreement prospectus is included in the $125,000,000 that may be sold by the Company under the base prospectus. As of September 30, 2016, no securities had been sold by the Company pursuant to the base prospectus or the sales agreement prospectus.

Table of Contents

At September 30, 2016, shares of common stock have been reserved for issuance as follows:


Options to purchase common stock - issued		2,738,486
Options to purchase common stock - unissued		410,377
Inducement grants - issued		306,945
Employee stock purchase plan - unissued		203,334
Warrants to purchase common stock		18,534
		3,677,676

6. Net Loss per Share

The Company excluded the following common stock equivalents, outstanding as of September 30, 2016 and 2015, from the computation of diluted net loss per share for the applicable quarterly periods because they had an anti-dilutive impact on the computation:



	September 30,
	2016	2015
Options to purchase common stock - issued	2,738,486	1,804,140
Inducement grants - issued	306,945	—
Unvested restricted common stock	—	590
Warrants to purchase common stock	18,534	18,534
Total	3,063,965	1,823,264

7. Subsequent Events

The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

Table of Contents

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our liquidity and future funding needs, our results of operations, financial condition, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein. Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of this report, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” section of our annual report on Form 10-K filed with the SEC for the year ended December 31, 2015 and in this Quarterly Report on Form 10-Q to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements as well as statements we make in our other reports filed with the SEC concerning our business development programs, financial condition and results of operations. You may obtain a copy of all reports we file with the SEC on our website at www.nivalis.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this report.

Overview

We are a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with cystic fibrosis. In addition to developing innovative solutions intended to extend and improve the lives of people with cystic fibrosis, we plan to utilize our proprietary S-nitrosoglutathione reductase, or GSNOR, inhibitor portfolio to develop therapeutics for other diseases.

Cystic fibrosis, or CF, is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominantly in the United States and Europe. CF is characterized by a defect in the chloride channel of human cells known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, which is caused by mutations in the CFTR gene. Our product candidate, cavosonstat (N91115), works through a novel mechanism of action called GSNOR inhibition to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect increases the amount of CFTR protein at the cell surface and the function of the CFTR chloride channel which, in turn, leads to an increase in net chloride secretion.

Nivalis discovered and owns exclusive rights to cavosonstat in the United States and all other major markets, including U.S. composition of matter patent protection until at least 2031. On July 7, 2016, we announced that the United States Adopted Names (USAN) Council had approved “cavosonstat” as the unique non-proprietary or generic name for N91115.

Table of Contents

We completed a Phase 1b clinical trial of cavosonstat in people with CF with two copies of the F508del-CFTR mutation in September 2015. The randomized, double-blind, placebo-controlled, parallel group study of orally administered cavosonstat demonstrated favorable safety, tolerability and pharmacokinetics of various doses of cavosonstat (50, 100 and 200 mg twice daily) in a total of 51 people with CF. Furthermore, a trend toward a modest reduction in sweat chloride, a marker of CFTR activity, was observed in the highest dose tested. This reduction in sweat chloride was statistically significant within group but not when compared with placebo.

During November 2015, we initiated a Phase 2, 12-week, double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy and safety of cavosonstat in 135 adult patients with CF who have two copies of the F508del-CFTR mutation and are being treated with Orkambi™ (lumacaftor/ivacaftor). In early July 2016, we announced completion of enrollment in 138 adult patients for this clinical trial, defined as the last patient enrolled receiving their first study dose. We currently expect to present topline results from this trial by the end of 2016.

During May 2016, we began dosing patients in a Phase 2, proof-of-concept study to further evaluate the effect of cavosonstat in patients who have one copy of the F508del-CFTR mutation and a second mutation that results in a gating defect in the CFTR protein. The study is designed to evaluate the efficacy and safety of cavosonstat in adult patients who have these mutations and who are being treated with Kalydeco™ (ivacaftor). We currently expect to present topline results from this trial in the first half of 2017.

Our operations to date have focused on discovery and development of our portfolio of GSNOR inhibitors, including cavosonstat and N6022. N6022 was the first product candidate to emerge from our GSNOR inhibitor portfolio and was optimized for inhaled delivery. In order to provide translational evidence of GSNOR’s role in lung disease, we initially explored the effects of N6022 in patients with mild asthma using an intravenous formulation. N6022 demonstrated a significant, beneficial effect on the airways in these patients, thus confirming the beneficial effects of N6022 observed in our preclinical studies of asthma. N6022 paved the way for cavosonstat by establishing initial safety of the class in healthy subjects and patients with CF. Because an oral dosage form is preferable in CF, a systemic disease that is not confined to the lungs, we elected to discontinue further development of N6022 in the chronic management of CF, but we may pursue development of N6022 in an inhaled dosage form for other potential indications.

During June 2015, we completed our initial public offering, or IPO, of an aggregate 6,325,000 shares of common stock at a price to the public of $14.00 per share for aggregate gross proceeds of $88.6 million, before $9.8 million in underwriting commissions and discounts and offering expenses. Our common stock is listed on the NASDAQ Global Market under the symbol “NVLS”. In July, 2016, we entered into a Sales Agreement with Cowen and Company, LLC pursuant to which we may sell up to $20,000,000 in shares of our common stock to the public from time to time in an at-the-market offering pursuant to an effective shelf registration statement on Form S-3 we have filed with the Securities and Exchange Commission. As of September 30, 2016, no securities had been sold under the Sales Agreement.

Since inception, we have financed our operations primarily through the proceeds from our IPO in June 2015 as well as private placements of equity and convertible debt prior to the IPO. From our inception in July 2003 to September 30, 2016, we raised $220.0 million in net proceeds from these sources. As of September 30, 2016, we had cash, cash equivalents and marketable securities of $66.2 million and no debt.

We have incurred losses from operations in each year since our inception. Our net losses were $7.4 million and $23.8 million for the three and nine months ended September 30, 2016, respectively. As of September 30, 2016, we had an accumulated deficit of $172.6 million. We expect to continue incurring losses for the foreseeable future as we advance our lead product candidate, cavosonstat, through clinical development, regulatory approval and, if approved, commercialization. We expect that research and development expenses will increase as we continue to develop our product candidates, and general and administrative costs may increase as we operate as a public company. We anticipate that we will need to raise additional capital, in addition to the IPO proceeds raised in June 2015, prior to the commercialization of cavosonstat or any other potential product candidate. Until such time that we can generate revenue from product sales, which, based on our current development plans, we do not expect to occur until 2019 at the earliest, we expect to finance our operating activities primarily through selling equity, incurring debt, entering into partnerships, and obtaining grants or seeking other nondilutive sources of financing. However, we may be unable to raise additional

Table of Contents

funds or enter into such arrangements when needed on favorable terms, if at all. Our failure to raise capital when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. It could force us to delay, limit, reduce or terminate our research and development programs and commercialization efforts or cause us to cease operations in full.

Financial Operations Overview

Revenue

To date, we have not generated any revenue. In the future, we may generate revenue from sales or licensing of cavosonstat or other potential product candidates. Based on our current development plans, however, we do not expect to generate product revenue until 2019 at the earliest. If we fail to complete the clinical development of a cavosonstat-based therapy, our ability to generate future revenue, and our results of operations and financial position, will be adversely affected.

Research and Development Expense

Research and development expense consists of costs incurred for the development of our product candidates, which include:

direct program expenses, which are costs incurred for contract research organizations, or CROs, clinical investigators, clinical consultants and clinical sites that will conduct our preclinical studies and clinical trials as well as costs associated with acquiring, developing and manufacturing preclinical and clinical supplies;

employee-related expenses, including salaries, benefits, stock-based compensation expense and other compensation costs;

costs associated with regulatory filings; and

costs of laboratory supplies, facilities, depreciation, travel and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other operating costs related to research and development.

Research and development costs are expensed as incurred. Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development primarily due to the increased size and duration of later-stage clinical trials. Thus, we expect our research and development expenses to increase for the foreseeable future as we seek to advance clinical development of our lead product candidate, cavosonstat.

Below is a summary of our research and development expenses by categories of costs for the periods presented. The other expenses category includes travel, lab and office supplies, clinical trial management software license fees, business insurance and other miscellaneous expenses.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
	(in thousands)
Direct program expenses
Cavosonstat for cystic fibrosis	$	3,249	$	2,534	$	10,835	$	6,969
Personnel and other expenses
Salaries, benefits and stock-based compensation		1,730		1,209		4,870		3,548
Consulting and outsourced services		237		107		458		244
Facilities and depreciation		87		68		254		203
Other expenses		366		361		1,243		797
Total research and development expenses	$	5,669	$	4,279	$	17,660	$	11,761

All of our research and development expenses for the nine months ended September 30, 2016 and 2015 relate to the development of cavosonstat. We have expended an aggregate of approximately $27.5 million for direct program expenses related to cavosonstat from inception through September 30, 2016. The successful development of cavosonstat

Table of Contents

or any other potential product candidate is uncertain. We cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when the period in which we receive material net cash inflows may commence, from cavosonstat or any other potential product candidate. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials which vary significantly over the life of a project as a result of differences arising during clinical development, including:

the number and results of our clinical trials;

the number of clinical sites included in the trials;

the number of patients who ultimately participate in the trials;

the length of time required to enroll suitable patients and complete the trials; and

the ability to obtain a drug supply for our trials.

Our expenditures are subject to additional uncertainties, including the commercial uptake of Orkambi, our preclinical study and clinical trial expenses, our costs to acquire, develop and manufacture preclinical study and clinical trial materials, the timing of regulatory approval for cavosonstat and post-commercialization and other incremental research and development costs for cavosonstat or any other potential product candidate. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. Changes in variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration, or FDA, or other regulatory authorities were to require us to conduct preclinical studies or clinical trials beyond those which we anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the clinical development of our product candidates and we may not obtain results from trials that are delayed when anticipated.

General and Administrative Expense

General and administrative expense consists principally of salaries and related costs not included in research and development expenses, including stock-based compensation, for personnel in executive, finance, business development and information technology functions, facility costs and professional fees for legal, patent review, consulting and accounting services.

Interest Income

Interest income for the three and nine months ended September 30, 2016 and 2015 consists of interest earned on marketable securities and money market funds.

Table of Contents

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2016 and 2015.

Research and Development Expenses. Research and development expenses for the three and nine months ended September 30, 2016 and 2015 were as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016			2015
	(in thousands)
Research and development expenses	$	5,669		$	4,279	$	17,660		$	11,761
Increase from prior period	$	1,390			—	$	5,899			—
% change from prior period		32.5	%		—		50.2	%		—

The increase in research and development expenses for the three months ended September 30, 2016 compared to the same period in the prior year was primarily due to $1.6 million of cavosonstat clinical trial expenses for the Phase 2 trial that was initiated in November 2015 and reached 100% patient enrollment as planned in early July 2016. A second Phase 2 trial initiated in March 2016 added $589,000 of clinical trial expenses for the three months ended September 30, 2016. During the third quarter of the prior year, we incurred $1.0 million of clinical trial expenses for our Phase 1b trial. This study was completed in September 2015 and therefore slightly offset the increases in the Phase 2 clinical study costs during the current quarter. Personnel and other expenses increased by $675,000 during the three months ended September 30, 2016 compared to the same period of the prior year. These increases were primarily the result of increased salaries, benefits and stock-based compensation expense.

The increase in research and development expenses for the nine months ended September 30, 2016 compared to the same period in the prior year was primarily due to $6.3 million of cavosonstat clinical trial expenses for the Phase 2 trial that was initiated in November 2015. A second Phase 2 trial initiated in March 2016, added $1.3 million of expense for the nine months ended September 30, 2016. During the first nine months of the prior year our Phase 1b trial incurred $3.3 million of clinical trial expenses. This study was completed in September 2015 and therefore slightly offset the Phase 2 clinical study costs in 2016. Personnel and other expenses increased by $2.0 million during the nine months ended September 30, 2016 compared to the same period of the prior year. These increases were primarily the result of increased salaries, benefits and stock-based compensation expense.

General and Administrative Expenses. General and administrative expenses for the three and nine months ended September 30, 2016 and 2015 were as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016			2015
	(in thousands)
General and administrative expenses	$	1,879		$	1,822	$	6,418		$	4,507
Increase from prior period	$	57			—	$	1,911			—
% change from prior period		3.1	%		—		42.4	%		—

The total general and administrative expenses for the three months ended September 30, 2016 and 2015 were at similar levels. The increase in general and administrative expenses for the nine months ended September 30, 2016 compared to the same period in the prior year was primarily due to increased expenses related to operating as a publicly-traded company, including increased investor relations, marketing expenses, and patent expenses. These expense categories on a combined basis increased by $941,000 during the nine months ended September 30, 2016, compared with the same period in the prior year. Additionally, stock-based compensation expense increased by $853,000 during the nine months ended September 30, 2016, compared with the same period in the prior year, primarily due to stock options granted in September 2015.

Table of Contents

Interest Income. Interest income for the three and nine months ended September 30, 2016 and 2015 were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
	(in thousands)
Interest income	$	115	$	12	$	328	$	13

The increase in interest income during 2016 over the prior year three- and nine-month periods was due to higher investment interest rates earned on a higher average cash and marketable securities balance following the completion of our IPO during June 2015.

Liquidity and Capital Resources

Since inception, we have funded our operations primarily through the proceeds from our IPO in June 2015 as well as private placements of equity and convertible debt prior to the IPO. As of September 30, 2016, we had cash, cash equivalents and marketable securities of $66.2 million and no debt.

The following table sets forth the primary sources and uses of cash for the nine months ended September 30, 2016 and 2015:


	Nine Months Ended September 30,
	2016		2015
	(in thousands)
Net cash used in operating activities	$	(21,082)	$	(13,806)
Net cash provided by (used in) investing activities		12,156		(35,223)
Net cash provided by financing activities		103		78,772
Net increase (decrease) in cash and cash equivalents	$	(8,823)	$	29,743

Operating Activities

During the first nine months of fiscal 2016, our net loss of $23.8 million included noncash charges of $2.4 million, primarily associated with stock-based compensation. During this same period, our net operating liabilities, excluding cash, cash equivalents and marketable securities, increased by $305,000 from the prior year period, and thus decreased our net cash used in operating activities to $21.1 million. The increase in net operating liabilities is primarily related to higher accrued direct program expenses of $1.3 million, slightly offset by decreases in accrued employee benefits of $330,000, decreases in accrued other liabilities of $151,000 and increases in prepaid expenses of $514,000. Increases in accrued direct program expenses were directly related to research and development costs for our two Phase 2 clinical trials. Accrued employee benefit costs decreased due to payment of 2015 employee performance bonuses during February 2016, slightly offset by accrued bonus expense for the 2016 period. Prepaid expenses increased due to the timing of various prepayments including insurance policies.

During the first nine months of fiscal 2015, our net loss of $16.3 million included noncash charges of $765,000, primarily associated with stock based compensation. During this same period, our net operating liabilities, excluding cash, cash equivalents and marketable securities, increased by approximately $1.7 million and thus decreased our net cash used in operating activities to $13.8 million. Net operating liabilities increased primarily because of higher accrued employee benefits of $1.1 million, increases in accounts payable and accrued direct program expenses of $836,000, and were slightly offset by increases in prepaid expenses of $366,000. Accrued employee benefit costs increased due to implementation of the 2015 employee incentive plan that was initiated at the beginning of the year. Increases in accounts payable and accrued direct program expenses were directly related to research and development costs for our Phase 1b clinical trial which began in the first quarter of 2015. Prepaid expenses increased due to higher prepaid premium costs for Directors and Officers insurance, upon becoming a public company.

Table of Contents

Investing Activities

The net cash provided by investing activities of $12.2 million for the nine months ended September 30, 2016 was primarily related to proceeds from maturities and sales of marketable securities outweighing our purchases of replacement securities during the period.

The net cash used in investing activities of $35.2 million for the nine months ended September 30, 2015 was primarily related to the purchase of marketable securities.

Financing Activities

The cash provided by financing activities for the nine months ended September 30, 2016 was related to the exercise of stock options and shares issued under the employee stock purchase plan.

The cash provided by financing activities for the nine months ended September 30, 2015 resulted from $78.8 million of net proceeds for the sale of common stock in our IPO that closed during June 2015.

Funding Requirements

We believe our existing cash, cash equivalents and marketable securities will provide resources to complete our two ongoing Phase 2 clinical trials and with successful clinical outcomes, to fund substantial patient enrollment in our Phase 3 clinical program in cystic fibrosis. We have based these estimates on assumptions that may prove to be incorrect, and given the risks and uncertainties associated with drug development and commercialization, we could require greater or additional capital resources sooner than expected. Our present and future funding requirements will depend on many factors, including but not limited to:

the scope, progress, results and costs of preclinical development and clinical trials of cavosonstat and any other product candidate;

our ability to advance the clinical development program for our lead product candidate, cavosonstat;

personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation costs;

the costs, timing and outcome of regulatory review of cavosonstat or any other potential product candidate;

the revenue, if any, received from commercial sales of cavosonstat or any other potential product candidate for which we, or any future partner, may receive marketing approval;

the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for cavosonstat or any other potential product candidate for which we receive marketing approval and do not partner for commercialization; and

the extent to which we acquire, in-license or out-license other products and technologies.

Existing cash, cash equivalents and marketable securities will not be sufficient to fund our operations through successful development and commercialization of cavosonstat or any other potential product candidate. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of our planned development and commercialization activities, which could harm our business. For more information as to the risks associated with our future funding requirements, see the risk factors under Item 1A. – “Risk Factors” of this Quarterly Report on Form 10-Q and under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 that we have filed with the SEC.

In July, 2016, we entered into a Sales Agreement with Cowen and Company, LLC pursuant to which we may sell up to $20,000,000 in shares of our common stock to the public from time to time in an at-the-market offering pursuant to an effective shelf registration statement on Form S-3 we have filed with the Securities and Exchange Commission. As of September 30, 2016, no securities had been sold under the Sales Agreement.

Table of Contents

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 that we have filed with the SEC. There have not been any material changes to our critical accounting policies since December 31, 2015.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations at September 30, 2016:


	Payments due by period
	(in thousands)
	(unaudited)
	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Purchase obligations	$	7,483	$	5,900	$	1,583	$	—	$	—
Operating leases		449		296		153		—		—
Total obligations	$	7,932	$	6,196	$	1,736	$	—	$	—

We have entered into contracts with third parties to provide future services, which include research and development, clinical development support and testing services. These purchase obligations indicated above include both cancellable and non-cancellable amounts. We also have an operating lease obligation for office and laboratory space, which will expire on March 31, 2018. We have the option to renew the lease for an additional three-year term and the option to terminate the lease at any time after March 31, 2017, for a termination fee of $25,000.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet activities, as defined in Item 303(a)(4) of Regulation S-K.

Recent Accounting Pronouncements

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, as well as classification within the statement of cash flows. The guidance will be effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the impact of the new pronouncement on our financial statements.

For additional discussion of recent accounting pronouncements please refer to Note 3, “Summary of Significant Accounting Policies – Recent Accounting Pronouncements”, in our previously filed Annual Report on Form 10-K for the year ended December 31, 2015. There were no new accounting pronouncements adopted during the six months ended June 30, 2016 that had a material effect on our financial statements.

Table of Contents

We qualify as an “emerging growth company” pursuant to the provisions of the JOBS Act, which allows us to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we irrevocably chose to “opt out” of such extended transition period, and as a result, we plan to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of September 30, 2016, we had cash, cash equivalents and marketable securities of $66.2 million, consisting of deposits with commercial banks in checking, interest-bearing and demand money market accounts, reverse repurchase agreements, corporate debt securities, U.S. treasury securities and obligations of U.S. government agencies. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs.

Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a−15(e) promulgated under the Exchange Act, that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. In connection with the filing of this Quarterly Report on Form 10-Q, an evaluation was carried out by our management, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2016.

Changes in Internal Control over Financial Reporting

This Quarterly Report on Form 10-Q does not include a report on changes in our internal controls over financial reporting that occurred during our most recent fiscal quarter due to a transition period established by the Exchange Act for newly public companies.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

We are not currently a party to any legal proceedings.

ITEM 1A.RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to carefully consider the risk factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There have been no material changes to the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, 2015. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Use of Proceeds

Our initial public offering, or IPO, of common stock was effected through a Registration Statement on Form S-1 (File No. 333-204127) declared effective by the SEC on June 16, 2015. On June 22, 2015, we sold 6,325,000 shares of common stock, including 825,000 shares sold to the underwriters pursuant to their option to purchase such shares to cover over allotments, at an initial public offering price of $14.00 per share, for aggregate gross proceeds of $88.6 million and net proceeds of $78.8 million after deducting underwriting discounts and commissions and expenses. The underwriters of the offering were Cowen & Company, LLC, Stifel, Nicolaus & Company, Incorporated, Robert W. Baird & Co., Incorporated and H.C. Wainwright & Co., LLC. Following the sale of the shares in connection with the closing of the IPO, the offering terminated.

Through September 30, 2016, we had used $12.6 million of our IPO proceeds for working capital and general corporate expenses. There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus for the offering filed with the SEC pursuant to Rule 424(b).

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.OTHER INFORMATION

None.

ITEM 6.EXHIBITS

(a) Exhibits

The exhibits listed on the accompanying exhibit index are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.

Table of Contents

INDEX TO EXHIBITS


3.1	Amended and Restated Certificate of Incorporation of the Registrant (1)
3.2	Amended and Restated Bylaws of the Registrant (2)
4.1	Form Common Stock Certificate of the Registrant (2)
4.2	Second Amended and Restated Warrant to Purchase Common Stock, dated February 18, 2011, issued to Horizon Credit I, LLC (2)
4.3	Second Amended and Restated Warrant to Purchase Common Stock, dated February 18, 2011, issued to Horizon Credit I, LLC (2)
4.4	Second Amended and Restated Investor Rights Agreement dated November 18, 2014 (2)
31.1	Certification of the Registrant’s Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of the Registrant’s Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Registrant’s Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 101.SCH 101.CAL 101.LAB 101.PRE 101.DEF	XBRL Instance Document XBRL Taxonomy Extension Schema Document XBRL Taxonomy Extension Calculation Linkbase Document XBRL Taxonomy Extension Label Linkbase Document XBRL Taxonomy Extension Presentation Linkbase Document XBRL Taxonomy Extension Definition Linkbase Document
(1)	Incorporated by reference to the Registrant’s Registration Statement on Form S-8 (Registration No. 333-205220) filed on June 25, 2015.
(2)	Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-204127), filed on May 13, 2015.
*	Indicates a management contract or a compensatory plan, contract or arrangement.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: November 7, 2016	NIVALIS THERAPEUTICS, INC.

	By:	/s/ Jon Congleton
		Jon Congleton
		President and Chief Executive Officer; Director
		(Principal Executive Officer)

	By:	/s/ R. Michael Carruthers
		R. Michael Carruthers
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 nvls-20160930ex311eaa45a.htm EX-31.1 nvls_Ex_31-1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jon Congleton, President and Chief Executive Officer of Nivalis Therapeutics, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of Nivalis Therapeutics, Inc. for the quarter ended September 30, 2016;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2016

/s/ JON CONGLETON
Jon Congleton
President and Chief Executive Officer

EX-31.2 3 nvls-20160930ex31230070f.htm EX-31.2 nvls_Ex_31-2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, R. Michael Carruthers, Chief Financial Officer of Nivalis Therapeutics, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of Nivalis Therapeutics, Inc. for the quarter ended September 30, 2016;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2016

/s/ R. MICHAEL CARRUTHERS
R. Michael Carruthers
Chief Financial Officer

EX-32.1 4 nvls-20160930ex3219259ab.htm EX-32.1 nvls_Ex_32-1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Nivalis Therapeutics, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2016

/s/ JON CONGLETON
Jon Congleton
President and Chief Executive Officer

/s/ R. MICHAEL CARRUTHERS
R. Michael Carruthers

Chief Financial Officer

EX-101.INS 5 nvls-20160930.xml EX-101.INS 0001626199 us-gaap:OverAllotmentOptionMember 2015-06-22 2015-06-22 0001626199 us-gaap:IPOMember 2015-06-22 2015-06-22 0001626199 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001626199 us-gaap:RetainedEarningsMember 2016-09-30 0001626199 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001626199 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001626199 us-gaap:RetainedEarningsMember 2015-12-31 0001626199 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001626199 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001626199 us-gaap:CommonStockMember 2016-09-30 0001626199 us-gaap:CommonStockMember 2015-12-31 0001626199 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ExecutiveVicePresidentMember 2016-04-18 2016-04-18 0001626199 us-gaap:EmployeeStockOptionMember us-gaap:ExecutiveVicePresidentMember 2016-04-18 2016-04-18 0001626199 2015-06-22 2015-06-22 0001626199 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0001626199 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001626199 2016-07-01 2016-09-30 0001626199 2015-07-01 2015-09-30 0001626199 us-gaap:CommonStockMember nvls:SalesAgreementProspectusMember 2016-09-30 0001626199 us-gaap:CommonStockMember nvls:BaseProspectusMember 2016-09-30 0001626199 2015-06-30 0001626199 us-gaap:WarrantMember 2016-09-30 0001626199 nvls:StockOptionUnissuedMember 2016-09-30 0001626199 nvls:StockOptionIssuedMember 2016-09-30 0001626199 nvls:InducementGrantsIssuedMember 2016-09-30 0001626199 nvls:EmployeeStockPurchasePlanMember 2016-09-30 0001626199 2015-09-30 0001626199 2014-12-31 0001626199 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2016-09-30 0001626199 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-09-30 0001626199 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-09-30 0001626199 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2016-09-30 0001626199 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2015-12-31 0001626199 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0001626199 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0001626199 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2015-12-31 0001626199 us-gaap:RepurchaseAgreementsMember 2016-09-30 0001626199 us-gaap:MoneyMarketFundsMember 2016-09-30 0001626199 us-gaap:CashMember 2016-09-30 0001626199 us-gaap:RepurchaseAgreementsMember 2015-12-31 0001626199 us-gaap:MoneyMarketFundsMember 2015-12-31 0001626199 us-gaap:CashMember 2015-12-31 0001626199 us-gaap:USTreasuryAndGovernmentMember 2016-09-30 0001626199 us-gaap:CorporateDebtSecuritiesMember 2016-09-30 0001626199 us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0001626199 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0001626199 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001626199 nvls:StockOptionIssuedMember 2016-01-01 2016-09-30 0001626199 nvls:InducementGrantsIssuedMember 2016-01-01 2016-09-30 0001626199 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001626199 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001626199 nvls:StockOptionIssuedMember 2015-01-01 2015-09-30 0001626199 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001626199 us-gaap:CommonStockMember nvls:BaseProspectusMember 2016-07-05 2016-07-05 0001626199 us-gaap:CommonStockMember nvls:SalesAgreementProspectusMember 2016-07-05 2016-07-05 0001626199 nvls:BaseProspectusMember 2016-07-05 2016-07-05 0001626199 2015-01-01 2015-09-30 0001626199 2016-09-30 0001626199 2015-12-31 0001626199 2016-10-31 0001626199 2016-01-01 2016-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q3 2016 2016-09-30 10-Q 0001626199 15543469 Yes Accelerated Filer Nivalis Therapeutics, Inc. 1555000 2837000 <div> <div> Accrued Direct Program Expenses Substantial portions of the Company’s preclinical studies and clinical trials, including the manufacture and packaging of drug supplies are performed by third-party laboratories, contract manufacturing organizations, medical centers, contract research organizations and other service providers (collectively vendors). These vendors generally bill monthly or quarterly for services performed or upon achieving certain milestones. For preclinical studies and product development and manufacturing, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon patient enrollment and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported by these vendors using software tracking systems, or through clinical site visits and vendor correspondence. Company estimates depend on the timeliness and accuracy of the data provided by these vendors regarding the status of each program and total program spending. The Company periodically evaluates these estimates to determine if adjustments are necessary or appropriate based on information received. <div /></div> </div> 213000 1282000 <div> <div> 2. Liquidity Risks The Company has incurred operating losses and has an accumulated deficit as a result of ongoing research and development spending. As of September 30, 2016, the Company had an accumulated deficit of $172.6 million. For the nine months ended September 30, 2016, net loss was $23.8 million and net cash used in operating activities was $21.1 million. The Company anticipates that operating losses and net cash used in operating activities will continue and substantially increase over the next several years as it expands development activities for its current product candidate cavosonstat (N91115). The Company has historically financed its operations primarily through the sale of its equity and debt securities. The Company will continue to be dependent upon such sources of funds until it is able to generate positive cash flows from its operations. Management has determined that the Company’s existing cash, cash equivalents and marketable securities as of September 30, 2016 will be sufficient to fund operations at least through the next twelve months. The Company expects to fund future operations through the sale of its equity securities, incurring debt, entering into partnerships, obtaining grants, or seeking other nondilutive sources of financing. There can be no assurance that sufficient funds from these sources will be available to the Company when needed or at all or on terms that are favorable to the Company. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it would have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. It could force the Company to delay, limit, reduce or terminate research and development programs and commercialization efforts or cause the Company to cease operations in full. <div /></div> </div> 125000000 20000000 3732412

994000

1012000

3000

5000

232309000

234670000

2259000

1823264

1804140

590

18534

3063965

306945

2738486

18534

87909000

67342000

87686000

67030000

223000

312000

26000

22000

4000

17000

3000

14000

23000

16000

7000

12000

87251000

1862000

38276000

12131000

6000000

28982000

66182000

2704000

26869000

8465000

5000000

23144000

87254000

1862000

38282000

12131000

6000000

28979000

73261000

12131000

73261000

66187000

2704000

26860000

8465000

5000000

23158000

55018000

8465000

55018000

<div> <div> Unaudited Interim Financial Data The balance sheet at December 31, 2015 was derived from the Company’s audited financial statements, but does not include all the disclosures required by GAAP. These financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2015. The accompanying interim financial statements as of September 30, 2016 and for the three and nine months ended September 30, 2016 and 2015, are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements, pursuant to the rules and regulations of the SEC for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary to fairly state the Company’s financial position as of September 30, 2016 and the results of operations and cash flows for the three and nine months ended September 30, 2016 and 2015. The results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any future interim period.   <div /></div> </div>

27812000

57555000

24991000

16168000

29743000

-8823000

<div> <div> 4. Cash, Cash Equivalents and Marketable Securities The following is a summary of cash, cash equivalents and marketable securities as of September 30, 2016 and December 31, 2015 (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross unrealized </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross unrealized </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair market </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized Cost </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> gains </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> losses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> value </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,704 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,704 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Reverse repurchase agreement </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S Treasury securities and obligations of U.S. government agencies </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,144 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,158 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,869 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,860 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total for September 30, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,182 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,187 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,862 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,862 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Reverse repurchase agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S Treasury securities and obligations of U.S. government agencies </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,982 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,979 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,276 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,282 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total for December 31, 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87,251 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87,254 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

3677676

203334

306945

2738486

410377

18534

0.001

200000000

15462030

15505334

15462030

15505334

15000

16000

-16240000

-6074000

-23748000

-7451000

41880000

47000

104000

-2.22

-0.39

-1.53

-0.48

<div> <div> 6. Net Loss per Share The Company excluded the following common stock equivalents, outstanding as of September 30, 2016 and 2015, from the computation of diluted net loss per share for the applicable quarterly periods because they had an anti-dilutive impact on the computation:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:19.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:19.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options to purchase common stock - issued </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,738,486 </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,804,140 </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Inducement grants - issued </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>306,945 </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested restricted common stock </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590 </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants to purchase common stock </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,534 </td> <td valign="middle" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,534 </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:76.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,063,965 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,823,264 </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

1675000

1345000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> for similar assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in active </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> for similar assets </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> markets for </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> observable in the </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> markets for </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> observable in the </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> identical assets  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> marketplace </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> identical assets  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> marketplace </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets measured at fair value: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market investments </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,261 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,261 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Fair Value Measurements In general, asset and liability fair values are determined using the following categories: Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities. Level 2 – inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. Level 3 – inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own estimates about the assumptions that a market participant would use in pricing as asset. The Company’s financial instruments, including money market investments, reverse repurchase agreements, corporate debt securities, U.S. Treasury securities and obligations of U.S. government agencies, are measured at fair value on a recurring basis. There were no transfers between levels for the nine months ended September 30, 2016. Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of September 30, 2016 and December 31, 2015 (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> for similar assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in active </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> for similar assets </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> markets for </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> observable in the </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> markets for </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> observable in the </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> identical assets  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> marketplace </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> identical assets  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> marketplace </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets measured at fair value: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market investments </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,261 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,261 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Fair Value of Financial Instruments The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts payable, accrued direct program expenses, and accrued employee benefits, and other financial instruments included within current assets or current liabilities.    <div /></div> </div>

4507000

1822000

6418000

1879000

-23750000

623000

18000

1126000

-330000

88000

-151000

-366000

-514000

13000

12000

328000

115000

87909000

67342000

4419000

5238000

62263000

50019000

78772000

103000

-35223000

12156000

-13806000

-21082000

-16255000

-6089000

-23750000

-7433000

-16255000

-23750000

<div> <div> Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, as well as classification within the statement of cash flows. The guidance will be effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently evaluating the impact of the new pronouncement on its financial statements. For additional discussion of recent accounting pronouncements please refer to Note 3, “Summary of Significant Accounting Policies – Recent Accounting Pronouncements”, in the Company’s previously filed Annual Report on Form 10-K for the year ended December 31, 2015. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2016 that had a material effect on its financial statements.   <div /></div> </div>

-16268000

-6101000

-24078000

-7548000

195000

44000

15000

2000

-18000

9800000

35081000

66154000

142000

90000

0.001

10000000

432000

843000

78800000

78772000

78400000

103000

11761000

4279000

17660000

5669000

-148837000

-172587000

718000

2259000

108333

216667

15462000

15505000

<div> <div> 3. Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include all adjustments necessary for the presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements and accompanying notes, including accrued liabilities and the fair value-based measurement of equity instruments. Actual results could differ materially from those estimates. The Company evaluates its estimates and assumptions as facts and circumstances dictate. Unaudited Interim Financial Data The balance sheet at December 31, 2015 was derived from the Company’s audited financial statements, but does not include all the disclosures required by GAAP. These financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2015. The accompanying interim financial statements as of September 30, 2016 and for the three and nine months ended September 30, 2016 and 2015, are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements, pursuant to the rules and regulations of the SEC for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary to fairly state the Company’s financial position as of September 30, 2016 and the results of operations and cash flows for the three and nine months ended September 30, 2016 and 2015. The results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any future interim period.   Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing and demand money market accounts.   Marketable Securities The Company has designated marketable securities as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are classified as available-for-sale are carried at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders' equity until their disposition. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company’s then current intent and ability to sell the security if it is required to do so. The cost of securities sold is based on the specific identification method. All marketable securities are subject to a periodic impairment review. The Company will recognize an impairment charge when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.   Accrued Direct Program Expenses Substantial portions of the Company’s preclinical studies and clinical trials, including the manufacture and packaging of drug supplies are performed by third-party laboratories, contract manufacturing organizations, medical centers, contract research organizations and other service providers (collectively vendors). These vendors generally bill monthly or quarterly for services performed or upon achieving certain milestones. For preclinical studies and product development and manufacturing, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon patient enrollment and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported by these vendors using software tracking systems, or through clinical site visits and vendor correspondence. Company estimates depend on the timeliness and accuracy of the data provided by these vendors regarding the status of each program and total program spending. The Company periodically evaluates these estimates to determine if adjustments are necessary or appropriate based on information received.   Comprehensive Loss Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on the Company’s investments in available-for-sale marketable securities. The Company presents comprehensive loss and its components in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2016.   Net Loss per Share The Company reports net loss per share in accordance with the standard codification of ASC “Earnings per Share” (“ASC 260”). Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could be exercised or converted into common shares, and is computed by dividing net loss by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share excludes the impact of options to purchase common stock, restricted stock units and warrants to purchase common stock, as the effect would be anti-dilutive. During a loss period, the assumed exercise of in-the-money stock options and other potentially diluted instruments has an anti-dilutive effect and therefore, these instruments are excluded from the computation of dilutive earnings per share.   Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, as well as classification within the statement of cash flows. The guidance will be effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently evaluating the impact of the new pronouncement on its financial statements. For additional discussion of recent accounting pronouncements please refer to Note 3, “Summary of Significant Accounting Policies – Recent Accounting Pronouncements”, in the Company’s previously filed Annual Report on Form 10-K for the year ended December 31, 2015. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2016 that had a material effect on its financial statements.   Fair Value of Financial Instruments The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts payable, accrued direct program expenses, and accrued employee benefits, and other financial instruments included within current assets or current liabilities.    Fair Value Measurements In general, asset and liability fair values are determined using the following categories: Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities. Level 2 – inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. Level 3 – inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own estimates about the assumptions that a market participant would use in pricing as asset. The Company’s financial instruments, including money market investments, reverse repurchase agreements, corporate debt securities, U.S. Treasury securities and obligations of U.S. government agencies, are measured at fair value on a recurring basis. There were no transfers between levels for the nine months ended September 30, 2016. Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of September 30, 2016 and December 31, 2015 (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted prices </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in active </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> for similar assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in active </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> for similar assets </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> markets for </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> observable in the </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> markets for </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> observable in the </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> identical assets  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> marketplace </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> identical assets  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> marketplace </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets measured at fair value: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market investments </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,261 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,261 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

83490000

62104000

83490000

3000

232309000

15000

-148837000

62104000

5000

234670000

16000

-172587000

43000

6325000

875000

103000

102000

1000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross unrealized </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross unrealized </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair market </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized Cost </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> gains </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> losses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> value </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,704 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,704 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,465 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Reverse repurchase agreement </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S Treasury securities and obligations of U.S. government agencies </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,144 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  - </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,158 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,869 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,860 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total for September 30, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,182 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,187 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,862 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,862 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,131 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Reverse repurchase agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  – </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S Treasury securities and obligations of U.S. government agencies </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,982 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,979 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,276 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,282 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total for December 31, 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87,251 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87,254 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

7322000

15451000

15476000

15504000

EX-101.SCH 6 nvls-20160930.xsd EX-101.SCH 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Liquidity Risks link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Cash, Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Liquidity Risks (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies (Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stockholders' Equity (Reserved) (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nvls-20160930_cal.xml EX-101.CAL EX-101.DEF 8 nvls-20160930_def.xml EX-101.DEF EX-101.LAB 9 nvls-20160930_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Balance Sheets Assets. Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Marketable Securities, Current Marketable securities Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Assets, Noncurrent Property and equipment and other assets, net Assets Total assets Liabilities and stockholders' deficit Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued expense that are directly related to goods produced and sold and services rendered during the reporting period. Accrued Direct Program, Current Accrued direct program expenses Employee-related Liabilities, Current Accrued employee benefits Other Accrued Liabilities, Current Accrued other liabilities Liabilities, Current Total current liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding for both periods presented Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 shares authorized for both periods presented; 15,505,334 and 15,462,030 shares issued and outstanding, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Authorized preferred stock (in shares) Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statements of Operations and Comprehensive Loss Revenues Revenue Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Income (Loss) Loss from operations Interest Income (Expense), Nonoperating, Net Interest income Net Income (Loss) Attributable to Parent Net loss attributable to common stockholders Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gains (losses) on marketable securities Unrealized gains on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net loss Comprehensive loss Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares outstanding - basic and diluted (in shares) Earnings Per Share, Basic and Diluted Net loss per share - basic and diluted (in dollars per share) Statement of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income Retained Earnings [Member] Accumulated Deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance, ending Balance, beginning Shares, Outstanding Balance, ending (in shares) Balance, beginning (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Employee stock-based compensation expense Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under employee share plans and awards Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under employee share plans and awards (in shares) Income (Loss) from Operations before Extraordinary Items Net loss Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Net Income (Loss) Available to Common Stockholders, Basic Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Share-based Compensation Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the reporting period in the accrued expense that are directly related to goods produced and sold and services rendered in an entity's business. Increase (Decrease) in Accrued Direct Program Accrued direct program expenses Increase (Decrease) in Employee Related Liabilities Accrued employee benefits Increase (Decrease) in Other Accrued Liabilities Accrued other liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Available-for-sale Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from sales and maturities of marketable securities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of offering costs Proceeds from Stock Options Exercised Proceeds from employee stock purchases and stock options exercised Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information Conversion of Stock, Amount Converted Conversion of convertible preferred stock to common stock Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Description of Business Liquidity Risks The entire disclosure related to the entity's liquidity. Liquidity Risk Liquidity Risks Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Cash, Cash Equivalents and Marketable Securities Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Subsequent Events Subsequent Events [Text Block] Subsequent Events Use of Estimates, Policy [Policy Text Block] Basis of Presentation and Use of Estimates Basis of Accounting [Text Block] Unaudited Interim Financial Data Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Marketable Securities, Policy [Policy Text Block] Marketable Securities Disclosure of accounting policy for accrued direct program expenses. Accrued Direct Program Expenses Policy Policy Text Block Accrued Direct Program Expenses Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Earnings Per Share, Policy [Policy Text Block] Net Loss per Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of assets measured at fair value on a recurring basis (in thousands) Unrealized Gain (Loss) on Investments [Table Text Block] Schedule of cash, cash equivalents and marketable securities (in thousands) Schedule of Stock by Class [Table] Class of Stock [Line Items] Stockholders' Equity Schedule of Stock by Class [Table Text Block] Schedule of common stock reserved for issuance Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive common stock equivalents Fair Value Measurements, Recurring and Nonrecurring [Table] Investment Type [Axis] Investment Type Categorization [Member] Investments [Domain] Money Market Funds [Member] Money market funds Debt Securities [Member] U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level 1 Fair Value Inputs Level2 [Member] Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Assets measured at fair value: Available-for-sale Securities, Current Fair market value Schedule of Available-for-sale Securities [Table] Cash [Member] Cash Repurchase Agreements [Member] Reverse repurchase agreements U S Treasury And Government [Member] U.S. Treasury securities and obligations of U.S. government agencies Corporate Debt Securities [Member] Corporate debt securities Schedule of Available-for-sale Securities [Line Items] Cash, Cash Equivalents and Marketable Securities Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax [Abstract] Summary of cash, cash equivalents and marketable securities Available-for-sale Securities, Amortized Cost Basis Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized gains Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Gross unrealized losses Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Employee Stock Option [Member] Options to purchase common stock Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] I P O [Member] IPO Over Allotment Option [Member] Underwriters' Over-Allotment Option Stock Issued During Period, Shares, New Issues Issuance of common stock, net of offering costs (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional number of shares authorized (in shares) Proceeds from Issuance Initial Public Offering Proceeds from issuance of common stock, net of offering costs Payments of Stock Issuance Costs Issuance of common stock, offering costs Represents the maximum potential amount of aggregate offering price that could be received under the registration of securities. Securities Registration Maximum Aggregate Offering Price Securities registration, maximum potential aggregate offering price Represents the maximum potential number of aggregate shares that may be issued and sold under a sales agreement. Securities Registration Maximum Aggregate Shares Issued And Sold Under Sales Agreement Maximum potential shares issued and sold under sales agreement An arrangement whereby the holder is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, which have been issued as of the report date. Stock Option Issued [Member] Options to purchase common stock - issued An arrangement whereby the holder is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, which have not been issued as of the report date. Stock Option Unissued [Member] Options to purchase common stock - unissued Stock options and restricted share units ("RSU") instruments granted as “inducement” awards under NASDAQ Marketplace Rules. Inducement Grants Issued [Member] Inducement grants - issued An employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee stock purchase plan - unissued Warrant [Member] Warrants to purchase common stock Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for issuance Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Restricted Stock [Member] Unvested restricted common stock Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Loss per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive common stock equivalents Scenario [Axis] Scenario Unspecified [Domain] Scenario, Unspecified [Domain] Represents the base prospectus. Base Prospectus [Member] Base Prospectus Represents the sales agreement prospectus. Sales Agreement Prospectus [Member] Sales Agreement Prospectus Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Relationship to Entity [Domain] Executive Vice President [Member] Executive Vice President Restricted Stock Units R S U [Member] Restricted stock units ("RSUs") EX-101.PRE 10 nvls-20160930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 31, 2016
Document and Entity Information
Entity Registrant Name	Nivalis Therapeutics, Inc.
Entity Central Index Key	0001626199
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		15,543,469
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 16,168	$ 24,991
Marketable securities	50,019	62,263
Prepaid expenses and other current assets	843	432
Total current assets	67,030	87,686
Property and equipment and other assets, net	312	223
Total assets	67,342	87,909
Current liabilities:
Accounts payable	1,012	994
Accrued direct program expenses	2,837	1,555
Accrued employee benefits	1,345	1,675
Accrued other liabilities	44	195
Total current liabilities	5,238	4,419
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding for both periods presented
Common stock, $0.001 par value; 200,000,000 shares authorized for both periods presented; 15,505,334 and 15,462,030 shares issued and outstanding, respectively	16	15
Additional paid-in capital	234,670	232,309
Accumulated other comprehensive income	5	3
Accumulated deficit	(172,587)	(148,837)
Total stockholders' equity	62,104	83,490
Total liabilities and stockholders' equity	$ 67,342	$ 87,909

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,505,334	15,462,030
Common stock, shares outstanding	15,505,334	15,462,030

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statements of Operations and Comprehensive Loss
Revenue			$ 0
Operating expenses:
Research and development	$ 5,669	$ 4,279	17,660	$ 11,761
General and administrative	1,879	1,822	6,418	4,507
Loss from operations	(7,548)	(6,101)	(24,078)	(16,268)
Interest income	115	12	328	13
Net loss attributable to common stockholders	(7,433)	(6,089)	(23,750)	(16,255)
Unrealized gains (losses) on marketable securities	(18)	15	2	15
Comprehensive loss	$ (7,451)	$ (6,074)	$ (23,748)	$ (16,240)
Weighted average shares outstanding - basic and diluted (in shares)	15,504	15,451	15,476	7,322
Net loss per share - basic and diluted (in dollars per share)	$ (0.48)	$ (0.39)	$ (1.53)	$ (2.22)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statement of Stockholders' Equity - 9 months ended Sep. 30, 2016 - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance, beginning at Dec. 31, 2015	$ 15	$ 232,309	$ 3	$ (148,837)	$ 83,490
Balance, beginning (in shares) at Dec. 31, 2015	15,462
Employee stock-based compensation expense		2,259			2,259
Issuance of common stock under employee share plans and awards	$ 1	102			103
Issuance of common stock under employee share plans and awards (in shares)	43
Unrealized gains on marketable securities			2		2
Net loss				(23,750)	(23,750)
Balance, ending at Sep. 30, 2016	$ 16	$ 234,670	$ 5	$ (172,587)	$ 62,104
Balance, ending (in shares) at Sep. 30, 2016	15,505

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Operating activities
Net loss	$ (23,750)	$ (16,255)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	104	47
Stock-based compensation expense	2,259	718
Changes in operating assets and liabilities:
Prepaid expenses and other	(514)	(366)
Accounts payable	18	623
Accrued direct program expenses	1,282	213
Accrued employee benefits	(330)	1,126
Accrued other liabilities	(151)	88
Net cash used in operating activities	(21,082)	(13,806)
Investing activities
Purchases of property and equipment	(90)	(142)
Purchases of marketable securities	(66,154)	(35,081)
Proceeds from sales and maturities of marketable securities	78,400
Net cash provided by (used in) investing activities	12,156	(35,223)
Financing activities
Proceeds from issuance of common stock, net of offering costs		78,772
Proceeds from employee stock purchases and stock options exercised	103
Net cash provided by financing activities	103	78,772
Net increase (decrease) in cash and cash equivalents	(8,823)	29,743
Cash and cash equivalents, beginning of period	24,991	27,812
Cash and cash equivalents, end of period	$ 16,168	57,555
Supplemental disclosures of cash flow information
Conversion of convertible preferred stock to common stock		$ 41,880

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business	9 Months Ended
Organization and Description of Business	Sep. 30, 2016
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business Nivalis Therapeutics, Inc. (the “Company” or “Nivalis”), incorporated in Delaware on August 1, 2012, is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with cystic fibrosis. In addition to developing innovative solutions intended to extend and improve the lives of people with cystic fibrosis, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Liquidity Risks	9 Months Ended
Liquidity Risks	Sep. 30, 2016
Liquidity Risks
Liquidity Risks	2. Liquidity Risks The Company has incurred operating losses and has an accumulated deficit as a result of ongoing research and development spending. As of September 30, 2016, the Company had an accumulated deficit of $172.6 million. For the nine months ended September 30, 2016, net loss was $23.8 million and net cash used in operating activities was $21.1 million. The Company anticipates that operating losses and net cash used in operating activities will continue and substantially increase over the next several years as it expands development activities for its current product candidate cavosonstat (N91115). The Company has historically financed its operations primarily through the sale of its equity and debt securities. The Company will continue to be dependent upon such sources of funds until it is able to generate positive cash flows from its operations. Management has determined that the Company’s existing cash, cash equivalents and marketable securities as of September 30, 2016 will be sufficient to fund operations at least through the next twelve months. The Company expects to fund future operations through the sale of its equity securities, incurring debt, entering into partnerships, obtaining grants, or seeking other nondilutive sources of financing. There can be no assurance that sufficient funds from these sources will be available to the Company when needed or at all or on terms that are favorable to the Company. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it would have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. It could force the Company to delay, limit, reduce or terminate research and development programs and commercialization efforts or cause the Company to cease operations in full.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

Unaudited Interim Financial Data

Cash and Cash Equivalents

Marketable Securities

Accrued Direct Program Expenses

Comprehensive Loss

Net Loss per Share

Recent Accounting Pronouncements

Fair Value of Financial Instruments

Fair Value Measurements

In general, asset and liability fair values are determined using the following categories:

Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities.

Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of September 30, 2016 and December 31, 2015 (in thousands):


			Quoted prices		Quoted prices				Quoted prices		Quoted prices
			in active		for similar assets				in active		for similar assets
			markets for		observable in the				markets for		observable in the
	September 30,		identical assets		marketplace		December 31,		identical assets		marketplace
Description	2016		(Level 1)		(Level 2)		2015		(Level 1)		(Level 2)
Assets measured at fair value:
Money market investments	$	8,465	$	8,465	$	—	$	12,131	$	12,131	$	—
U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements		55,018		—		55,018		73,261		—		73,261

XML 20 R10.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Marketable Securities

9 Months Ended

Sep. 30, 2016

Cash, Cash Equivalents and Marketable Securities

Cash, Cash Equivalents and Marketable Securities

4. Cash, Cash Equivalents and Marketable Securities

The following is a summary of cash, cash equivalents and marketable securities as of September 30, 2016 and December 31, 2015 (in thousands):


			Gross unrealized		Gross unrealized		Fair market
	Amortized Cost		gains		losses		value
September 30, 2016
Cash	$	2,704	$	-	$	-	$	2,704
Money market funds		8,465		-		-		8,465
Reverse repurchase agreement		5,000		-		-		5,000
U.S Treasury securities and obligations of U.S. government agencies		23,144		14		-		23,158
Corporate debt securities		26,869		3		(12)		26,860
Total for September 30, 2016	$	66,182	$	17	$	(12)	$	66,187

December 31, 2015
Cash	$	1,862	$	–	$	–	$	1,862
Money market funds		12,131		–		–		12,131
Reverse repurchase agreements		6,000		–		–		6,000
U.S Treasury securities and obligations of U.S. government agencies		28,982		4		(7)		28,979
Corporate debt securities		38,276		22		(16)		38,282
Total for December 31, 2015	$	87,251	$	26	$	(23)	$	87,254

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Stockholders' Equity

Stockholders' Equity

5. Stockholders’ Equity

Common Stock

At September 30, 2016, shares of common stock have been reserved for issuance as follows:


Options to purchase common stock - issued		2,738,486
Options to purchase common stock - unissued		410,377
Inducement grants - issued		306,945
Employee stock purchase plan - unissued		203,334
Warrants to purchase common stock		18,534
		3,677,676

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Net Loss per Share

9 Months Ended

Sep. 30, 2016

Net Loss per Share

Net Loss per Share

6. Net Loss per Share



	September 30,
	2016	2015
Options to purchase common stock - issued	2,738,486	1,804,140
Inducement grants - issued	306,945	—
Unvested restricted common stock	—	590
Warrants to purchase common stock	18,534	18,534
Total	3,063,965	1,823,264

XML 23 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2016
Subsequent Events
Subsequent Events	7. Subsequent Events The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

Unaudited Interim Financial Data

Cash and Cash Equivalents

Marketable Securities

Accrued Direct Program Expenses

Comprehensive Loss

Net Loss per Share

Recent Accounting Pronouncements

Fair Value of Financial Instruments

Fair Value Measurements

In general, asset and liability fair values are determined using the following categories:

Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities.

Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of September 30, 2016 and December 31, 2015 (in thousands):


			Quoted prices		Quoted prices				Quoted prices		Quoted prices
			in active		for similar assets				in active		for similar assets
			markets for		observable in the				markets for		observable in the
	September 30,		identical assets		marketplace		December 31,		identical assets		marketplace
Description	2016		(Level 1)		(Level 2)		2015		(Level 1)		(Level 2)
Assets measured at fair value:
Money market investments	$	8,465	$	8,465	$	—	$	12,131	$	12,131	$	—
U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements		55,018		—		55,018		73,261		—		73,261

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies

Schedule of assets measured at fair value on a recurring basis (in thousands)


			Quoted prices		Quoted prices				Quoted prices		Quoted prices
			in active		for similar assets				in active		for similar assets
			markets for		observable in the				markets for		observable in the
	September 30,		identical assets		marketplace		December 31,		identical assets		marketplace
Description	2016		(Level 1)		(Level 2)		2015		(Level 1)		(Level 2)
Assets measured at fair value:
Money market investments	$	8,465	$	8,465	$	—	$	12,131	$	12,131	$	—
U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements		55,018		—		55,018		73,261		—		73,261

XML 26 R16.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2016

Cash, Cash Equivalents and Marketable Securities

Schedule of cash, cash equivalents and marketable securities (in thousands)


			Gross unrealized		Gross unrealized		Fair market
	Amortized Cost		gains		losses		value
September 30, 2016
Cash	$	2,704	$	-	$	-	$	2,704
Money market funds		8,465		-		-		8,465
Reverse repurchase agreement		5,000		-		-		5,000
U.S Treasury securities and obligations of U.S. government agencies		23,144		14		-		23,158
Corporate debt securities		26,869		3		(12)		26,860
Total for September 30, 2016	$	66,182	$	17	$	(12)	$	66,187

December 31, 2015
Cash	$	1,862	$	–	$	–	$	1,862
Money market funds		12,131		–		–		12,131
Reverse repurchase agreements		6,000		–		–		6,000
U.S Treasury securities and obligations of U.S. government agencies		28,982		4		(7)		28,979
Corporate debt securities		38,276		22		(16)		38,282
Total for December 31, 2015	$	87,251	$	26	$	(23)	$	87,254

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Stockholders' Equity

Schedule of common stock reserved for issuance


Options to purchase common stock - issued		2,738,486
Options to purchase common stock - unissued		410,377
Inducement grants - issued		306,945
Employee stock purchase plan - unissued		203,334
Warrants to purchase common stock		18,534
		3,677,676

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2016

Net Loss per Share

Schedule of anti-dilutive common stock equivalents



	September 30,
	2016	2015
Options to purchase common stock - issued	2,738,486	1,804,140
Inducement grants - issued	306,945	—
Unvested restricted common stock	—	590
Warrants to purchase common stock	18,534	18,534
Total	3,063,965	1,823,264

XML 29 R19.htm IDEA: XBRL DOCUMENT

Liquidity Risks (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Liquidity Risks (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Liquidity Risks
Accumulated deficit	$ 172,587		$ 172,587		$ 148,837
Net loss	$ 7,451	$ 6,074	23,748	$ 16,240
Cash used in operating activities			21,082	$ 13,806
Revenues			$ 0

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Fair Value) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Assets measured at fair value:
Fair market value	$ 66,187	$ 87,254
Money market funds
Assets measured at fair value:
Fair market value	8,465	12,131
Money market funds \| Recurring
Assets measured at fair value:
Fair market value	8,465	12,131
Money market funds \| Recurring \| Level 1
Assets measured at fair value:
Fair market value	8,465	12,131
U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements \| Recurring
Assets measured at fair value:
Fair market value	55,018	73,261
U.S. Treasury securities, obligations of U.S. government agencies, corporate debt securities and reverse repurchase agreements \| Recurring \| Level 2
Assets measured at fair value:
Fair market value	$ 55,018	$ 73,261

XML 31 R21.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Summary of cash, cash equivalents and marketable securities
Amortized Cost	$ 66,182	$ 87,251
Gross unrealized gains	17	26
Gross unrealized losses	(12)	(23)
Fair market value	66,187	87,254
Cash
Summary of cash, cash equivalents and marketable securities
Amortized Cost	2,704	1,862
Fair market value	2,704	1,862
Money market funds
Summary of cash, cash equivalents and marketable securities
Amortized Cost	8,465	12,131
Fair market value	8,465	12,131
Reverse repurchase agreements
Summary of cash, cash equivalents and marketable securities
Amortized Cost	5,000	6,000
Fair market value	5,000	6,000
U.S. Treasury securities and obligations of U.S. government agencies
Summary of cash, cash equivalents and marketable securities
Amortized Cost	23,144	28,982
Gross unrealized gains	14	4
Gross unrealized losses		(7)
Fair market value	23,158	28,979
Corporate debt securities
Summary of cash, cash equivalents and marketable securities
Amortized Cost	26,869	38,276
Gross unrealized gains	3	22
Gross unrealized losses	(12)	(16)
Fair market value	$ 26,860	$ 38,282

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($)	Jul. 05, 2016	Apr. 18, 2016	Jun. 22, 2015	Sep. 30, 2016	Dec. 31, 2015	Jun. 30, 2015
Stockholders' Equity
Common stock, shares authorized				200,000,000	200,000,000	200,000,000
Authorized preferred stock (in shares)				10,000,000	10,000,000	10,000,000
Proceeds from issuance of common stock, net of offering costs			$ 78,800,000
Issuance of common stock, offering costs			$ 9,800,000
Shares issued				15,505,334	15,462,030
IPO
Stockholders' Equity
Issuance of common stock, net of offering costs (in shares)			6,325,000
Underwriters' Over-Allotment Option
Stockholders' Equity
Issuance of common stock, net of offering costs (in shares)			875,000
Executive Vice President \| Options to purchase common stock
Stockholders' Equity
Additional number of shares authorized (in shares)		108,333
Executive Vice President \| Restricted stock units ("RSUs")
Stockholders' Equity
Additional number of shares authorized (in shares)		216,667
Base Prospectus
Stockholders' Equity
Securities registration, maximum potential aggregate offering price	$ 125,000,000
Common Stock \| Base Prospectus
Stockholders' Equity
Maximum potential shares issued and sold under sales agreement	3,732,412
Shares issued				0
Common Stock \| Sales Agreement Prospectus
Stockholders' Equity
Securities registration, maximum potential aggregate offering price	$ 20,000,000
Shares issued				0

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Reserved) (Details)	Sep. 30, 2016 shares
Stockholders' Equity
Common stock reserved for issuance	3,677,676
Options to purchase common stock - issued
Stockholders' Equity
Common stock reserved for issuance	2,738,486
Options to purchase common stock - unissued
Stockholders' Equity
Common stock reserved for issuance	410,377
Inducement grants - issued
Stockholders' Equity
Common stock reserved for issuance	306,945
Employee stock purchase plan - unissued
Stockholders' Equity
Common stock reserved for issuance	203,334
Warrants to purchase common stock
Stockholders' Equity
Common stock reserved for issuance	18,534

XML 34 R24.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Details) - shares	9 Months Ended
Net Loss per Share (Details) - shares	Sep. 30, 2016	Sep. 30, 2015
Net Loss per Share
Antidilutive common stock equivalents	3,063,965	1,823,264
Options to purchase common stock - issued
Net Loss per Share
Antidilutive common stock equivalents	2,738,486	1,804,140
Inducement grants - issued
Net Loss per Share
Antidilutive common stock equivalents	306,945
Unvested restricted common stock
Net Loss per Share
Antidilutive common stock equivalents		590
Warrants to purchase common stock
Net Loss per Share
Antidilutive common stock equivalents	18,534	18,534

EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 36 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 61 105 1 false 29 0 false 3 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.nivalis.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://www.nivalis.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Balance Sheets (Parenthetical) Sheet http://www.nivalis.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Statements of Operations and Comprehensive Loss Sheet http://www.nivalis.com/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Statement of Stockholders' Equity Sheet http://www.nivalis.com/role/StatementStatementOfStockholdersEquity Statement of Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Statements of Cash Flows Sheet http://www.nivalis.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Organization and Description of Business Sheet http://www.nivalis.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 10201 - Disclosure - Liquidity Risks Sheet http://www.nivalis.com/role/DisclosureLiquidityRisks Liquidity Risks Notes 8 false false R9.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10401 - Disclosure - Cash, Cash Equivalents and Marketable Securities Sheet http://www.nivalis.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities Cash, Cash Equivalents and Marketable Securities Notes 10 false false R11.htm 10501 - Disclosure - Stockholders' Equity Sheet http://www.nivalis.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 10601 - Disclosure - Net Loss per Share Sheet http://www.nivalis.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 12 false false R13.htm 10701 - Disclosure - Subsequent Events Sheet http://www.nivalis.com/role/DisclosureSubsequentEvents Subsequent Events Notes 13 false false R14.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPolicies 14 false false R15.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30403 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) Sheet http://www.nivalis.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables Cash, Cash Equivalents and Marketable Securities (Tables) Tables http://www.nivalis.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities 16 false false R17.htm 30503 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.nivalis.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.nivalis.com/role/DisclosureStockholdersEquity 17 false false R18.htm 30603 - Disclosure - Net Loss per Share (Tables) Sheet http://www.nivalis.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.nivalis.com/role/DisclosureNetLossPerShare 18 false false R19.htm 40201 - Disclosure - Liquidity Risks (Details) Sheet http://www.nivalis.com/role/DisclosureLiquidityRisksDetails Liquidity Risks (Details) Details http://www.nivalis.com/role/DisclosureLiquidityRisks 19 false false R20.htm 40302 - Disclosure - Summary of Significant Accounting Policies (Fair Value) (Details) Sheet http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueDetails Summary of Significant Accounting Policies (Fair Value) (Details) Details http://www.nivalis.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 40401 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) Sheet http://www.nivalis.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesDetails Cash, Cash Equivalents and Marketable Securities (Details) Details http://www.nivalis.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables 21 false false R22.htm 40501 - Disclosure - Stockholders' Equity (Details) Sheet http://www.nivalis.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.nivalis.com/role/DisclosureStockholdersEquityTables 22 false false R23.htm 40502 - Disclosure - Stockholders' Equity (Reserved) (Details) Sheet http://www.nivalis.com/role/DisclosureStockholdersEquityReservedDetails Stockholders' Equity (Reserved) (Details) Details http://www.nivalis.com/role/DisclosureStockholdersEquityTables 23 false false R24.htm 40601 - Disclosure - Net Loss per Share (Details) Sheet http://www.nivalis.com/role/DisclosureNetLossPerShareDetails Net Loss per Share (Details) Details http://www.nivalis.com/role/DisclosureNetLossPerShareTables 24 false false All Reports Book All Reports nvls-20160930.xml nvls-20160930.xsd nvls-20160930_cal.xml nvls-20160930_def.xml nvls-20160930_lab.xml nvls-20160930_pre.xml true true ZIP 41 0001558370-16-009534-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-16-009534-xbrl.zip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end